Over viewhttps://HiPep.com

HiPep Laboratories focusing on bio-molecular recognition for healthcare
in the next generation, Looking for Exits: licensing out/collaboration

PIPA= Polyamides with Pyrrole and Imidazole as major building unites,
novel gene control drug candidates, sequence specific binding to dsDNA

OPOB= Discovery tools, high quality one cyclic peptide immobilized
on one gel-type bead + deconvolution technologies

Middle sized drugs such as peptide, designable & difficult toprepare, although HiPep established: Assembly, purificationand QC.
PIPA blocks binding of transcription factors inhibiting gene
expression, can control expression of gene.
Peptide Vehicle (THL, 55, 4091, 2014) DDS and DNAmodification alkylation of the target DNA
DNA visualization by labelled PIPAs
No-toxicities have been found, 3-4 weeks passed throughurine (～100%）
Target diseases: not possible by small molecules or antibodies
A list of synthetic PIPAs for clinical applications published asreagents http://hipep.jp/pdf/catalog/R002E.pdf

Instead of chip-plates, peptides areimmobilized on gel-type beads, one compoundon one bead, ca. 80 pico mol peptide/beadPioneer work by P. Dervan 1998：Science, 282, 111, Nature, 391, 468.

P/N：CP24OB, diversity 246 = ca 200
million: 19 natural & 5 non- proteogenic aminoacids, cyclic with D-Cys,NEW P/N：CP12OB: OPOB focusing on druglikeness and allowing rapid deconvolution(PAT.P), diversity = 3 million overcoming
limitations in ribosomal system such as displays
Nokihara, K., et.al., Amino Acids, 48, 2491-2499 ( 2016)
https://hipep.com/?p=3284

https://hipep.com/?p=2834

AGP for regenerative medicine = peptides exhibitingangiogenic and cell-adhesion properties and theirbioconjugates, longer lasting AGP for transplantation

PepTenChip® System: Biodetection technology with novel principles,disease-marker-independent, gives objective diagnostics

AGP

[2]
Structure activity relationship had been elicited.
NGF and/or bFGF have been used to give certain effects, although
infiltration has been observed. AGP showed no such effects, but theduration of actions has been relatively shorter and not enough forcomplete engraftment. Focusing on longer half-life time novel AGP hasbeen developed (PAT.P).
Assay using human cells, human umbilical vein endothelial cells, withquantitative evaluation were accomplished.
Stability was tested in cell lysate and human serum.
Cyclic AGPs contribute directly to neovascularization, no linear fragments
were generated in cell culture.
PAT. US, JP, EU; BBRC, 310, 153-157, 2003;
Bioorganic & Medicinal Chem, DOI:10.1016/j.bmc.2020.115685;
Int. J. Peptide Res and Therapeutics, DOI 10.1007/s10989-02210404-2.
https://hipep.com/?p=1559

The 4 key technologies for PepTenChip® system havebeen completed: de novo designed labeled structured
peptides as capture molecules; amorphous carbon,
novel chip substrates; array technology; a detector
for on-site use/maintenance free, PepTenCam. Most
attempts for the protein-chip development have been
failed and withdrew, due to the sensitivity andreproducibility by immobilization, instead solution
assays such as ELISA were the mainstream. The
PepTenChip® system does not involve detection of
specific molecules in a 1:1 manner, but its detection
principle is different (PAT: JP, US & EU).

The structural changes of analyte are reflected in the fluorescence intensity changes of capture
peptides in a dose dependent manner. This changes can be visualized as a pattern designated a“Protein Fingerprint”. Datamining is carried out by statistical analyses ： multivariate analyses.
Discovery of undefined materials related to diseases can be possible. PepTenChip® can be repeatedlyused (not disposable), Class I Medical device; noninvasive diagnostics; on-site “Point of Care”.
Objective results can be given not dependent on clinicians personal skill. Some clinical applications
are underway: (1) Precancer diagnostics for early detection using gastric juice, classification ofgastric precancerous lesions; (2) Multiple sclerosis (MS), of which cause
as well as positive disease markers are unknown, discrimination in MS
and related diseases using human spinal fluid for objective indicators,
not relying the skills of clinicians.
https://hipep.com/?p=781©HiPep Laboratories 2022